The largest database of trusted experimental protocols

Lal qcl 1000 assay

Manufactured by Lonza
Sourced in Switzerland, United States

The LAL QCL-1000 assay is a quantitative endotoxin detection system used to measure the presence and concentration of bacterial endotoxins in pharmaceutical and medical device products. The assay utilizes the Limulus Amebocyte Lysate (LAL) reaction to detect and quantify endotoxin levels. The system provides a reliable and accurate method for ensuring product safety and quality control.

Automatically generated - may contain errors

15 protocols using lal qcl 1000 assay

1

Quantification of Inflammatory Markers in Liver Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
To measure BT-related markers and proinflammatory cytokines, peripheral blood samples were collected on the same date of pre- and post-treatment HVPG measurements. Blood samples were separated by centrifugation at 1,500×g for 15 minutes within 30 minutes of collection. Samples were stored at −80°C until the analysis.
To determine LPS, serum samples were diluted 1:10 with pyrogen-free water and incubated for 10 minutes at 75°C to remove serum inhibitors. The concentration of LPS in serum was analyzed using the Limulus Amebocyte Lysate (LAL) assay, a quantitative chromogenic test for detecting endotoxins (QCL-1000 LAL assay; Lonza, Walkersville, MD, USA). The lower detection limit for LPS was 0.1 EU/mL. ELISA assays were used to quantitatively measure the serum concentration of LBP (HK315; Hycult Biotech, Uden, The Netherlands), IL-6 (Human Quantikine kits; R&D Systems, Minneapolis, MN, USA), and TNF-α (Human Quantikine kits) according to the manufacturers’ instructions. The absorbance at the 450-nm light wave was measured in each well with a microplate reader (BioTek ELX; BioTek, Shoreline, WA, USA). The lower limit of detection for LBP was 4.4 ng/mL, IL-6 was 0.70 pg/mL, and TNF-α was 0.5 pg/mL. All measurements were performed in duplicate and the mean value is presented.
+ Open protocol
+ Expand
2

Anion Exchange Chromatography Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
The protein of interest was exchanged into a 20 mM buffer suitable for anion exchange chromatography at a pH one unit below its isoelectric point, with 150 mM NaCl in addition. The isoelectric points were calculated using Geneious software (Biomatters, Auckland, New Zealand). The flow-through was collected after repeated passages through a 5 mL HiTrap Q HP anion exchange column (GE Healthcare, Pittsburgh, PA), and endotoxin levels were measured using the QCL-1000 LAL assay following the manufacturer’s instructions (Lonza, Basel, Switzerland).
+ Open protocol
+ Expand
3

Purification and Characterization of Salivary Proteins from Lu. intermedia

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eleven Lu. intermedia cDNA coding for secreted proteins (LinB-8, LinB-13, LinB-14, LinB-15, LinB-17, LinB-21, LinB-26, LinB-28, LinB-37, LinB-38, LinB-44) (Table 1)17 (link) were amplified by PCR, cloned into VR2010-TOPO and sequenced as described45 (link). Recombinant proteins were produced by transfection of 293-F cells (Invitrogen) with VR2010-TOPO plasmids coding for different Lu. intermedia salivary proteins by the Protein Expression Laboratory at the Frederick National Laboratory for Cancer Research (Frederick, MD). High-performance liquid chromatography purification of His-tagged Lu. intermedia salivary proteins was performed as described6 (link) using an NGC Chromatography System (BioRad). Eluted proteins were detected at 280 nm and collected every minute on a 96-well microtiter plate using a BioFrac Fraction Collector (BioRad). Recombinant proteins were tested for endotoxin using a QCL-1000 LAL assay (Lonza). Endotoxin-free recombinant proteins were used in all assays. Aliquots of eluted proteins were checked by SDS-PAGE developed by silver staining. Edman sequencing of the N-terminus region of the purified recombinant proteins was performed at the Protein Chemistry Section, Research Technology Branch, NIAID, NIH (Rockville, MD). Proteins were stored at −70 °C until use.
+ Open protocol
+ Expand
4

Murine Model of Allergic Sensitization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were anesthetized with isoflurane (IsoFlo; Abbott Laboratories,
Chicago, Ill) and their backs shaved with an electric razor 1 or 2 days before
first allergen exposure. A total of 250 μL of sterile saline solution,
OVA (albumin from chicken egg white, OVA grade V, Sigma-Aldrich, St Louis, Mo),
ASP (XPM110D3A4; Greer, Lenoir, NC), or both at a concentration of 1 mg/mL was
applied to a 2 × 2 cm patch of sterile gauze. The patch was secured with
TegaDerm (3M, Maplewood, Minn), and the mouse was wrapped with a Band-Aid and
waterproof tape. After 6 days, the patch was removed; 24 hours later, a new
patch was applied, for a total of 3 patches over a 3-week period, as shown in
Fig 1, A. Endotoxin levels in OVA and
ASP were assessed using the QCL-1000 LAL assay (Lonza, Basel, Switzerland): 1
mg/mL of OVA grade V contains about 250 EU/mL of endotoxin (50 EU/mL per patch),
and 1 mg/mL of ASP contains between 0.04 EU/mL (lot 357280) and 0.14 EU/mL (lot
194776).
+ Open protocol
+ Expand
5

Inflammatory Cytokine Profiling and LPS Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
IL-23, IL-17A, IL-8, TNF-α, GM-CSF, and IFN-γ were measured by ELISA kits (R&D Systems). Arginase I levels were also determined by an ELISA kit (BioVendor). Tissue LPS levels were analyzed in duplicate wells in 96-well plates according to the manufacturer’s instructions with Limulus Amoebocyte Lysate (LAL) assay QCL-1000 (Lonza, ValaisSwitzerland). The LPS levels were normalized back to the weight of the tissue samples used.
+ Open protocol
+ Expand
6

LPS and LBP Quantification in Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood was collected via cardiac puncture. LPS and LBP detection in the serum were based on a previously performed method (20 (link)). Circulating endotoxin (LPS) was analyzed using a Limulus Amoebocyte Lysate (LAL) assay QCL-1000 (Lonza AG, Valais Switzerland) in duplicate in 96-well plates according to the manufacturer's instructions; lipopolysaccharide-binding protein (LBP) levels were detected using the LBP Elisa kit (Abnova, Taipei, Taiwan). The lower limit of detection for each assay is 0.1 EU/ml for LPS and 5 ng/ml for LBP.
+ Open protocol
+ Expand
7

Quantifying Endotoxin and sCD163 Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma endotoxin (LPS) levels: Samples were diluted with LAL reagent in a ratio of 1:3 and heated at a temperature of 65 °C for half an hour. All samples were analyzed in replica according to the instructions, using the Limulus Amoebocyte Lysate (LAL) assay QCL-1000 (Lonza, Valais Switzerland).
Soluble CD163 (sCD163): Blood samples were collected in a 10-mL EDTA-coated tube, centrifuged and serum was then stored at − 80 °C. The samples were thawed and serum sCD163 was analyzed using the Quantikine enzyme-linked immunosorbent assay system (R&D Systems, Minneapolis, MN). The mean assay coefficient of variance was 3.3% for sCD163.
+ Open protocol
+ Expand
8

Quantifying Plasma LPS and CRP

Check if the same lab product or an alternative is used in the 5 most similar protocols
CB samples were centrifuged twice to separate plasma, which was stored at −80°C for batch analysis. Plasma was diluted to 10% or 20% with endotoxin free water and then heated to 85°C for 15 minutes to denature plasma proteins. Plasma levels of LPS were measured using a commercially available kit (Limulus Amebocyte Lysate [LAL] assay QCL-1000, Lonza, Walkersville, MD) according to the manufacturer's protocol. The lower level of detection for the assay was 0.7 pg/ml. Plasma levels of CRP were measured using a commercially available sandwich enzyme immunoassay kit and following manufacturer's protocol (Quantikine ELISA DCRP00, R&D, Minneapolis, MN). The minimum level of detection was 0.01 ng/ml.
+ Open protocol
+ Expand
9

Endotoxin Analysis via LAL Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Samples were diluted 1:3 with LAL reagent water and heat inactivated for 30min at 65°C. All samples were analyzed in duplicate according to the manufacturer’s instructions, using the Limulus Amoebocyte Lysate (LAL) assay QCL-1000 (Lonza, Valais Switzerland).
+ Open protocol
+ Expand
10

Production and Purification of Recombinant Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant (fusion) proteins were produced as previously described [13] (link). In short, gene amplified PCR products were cloned by Gateway Technology (Invitrogen, San Diego, CA, USA) in a bacterial expression vector containing an N-terminal hexa-histidine (His) tag. Generated vectors were sequenced to confirm correct insertion of the product. Recombinant proteins were overexpressed in Escherichia coli strain BL21 (DE3) and further purified. The size and purity of the proteins were analyzed by gel electrophoresis, using Coomassie brilliant blue and Western blotting using an anti-His antibody (Invitrogen, Carlsbad, CA, USA). Endotoxin contents were below 50 EU (endotoxin unit) per mg of recombinant protein as tested using a Limulus Amebocyte Lysate (LAL) QCL-1000 assay (LonzaInc., Basel, Switzerland). Recombinant proteins were tested to exclude protein non-specific T-cell stimulation and cellular toxicity in IFN-γ release assays using PBMC of in vitro PPD-negative, healthy Dutch donors recruited at the Blood Bank Sanquin, Leiden, The Netherlands [14] (link), [15] (link). None of these controls had experienced any known prior contact with TB patients.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!